TransMedics (NSDQ:TMDX) announced today that the Nasdaq market halted trading of the company’s common stock.
Andover, Mass.-based TransMedics, which develops organ transplant transportation platforms, saw its common stock close down -5.3% at $31.69 yesterday.
The company awaits the outcome of today’s meeting of the FDA’s Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, set to review the premarket approval application for its Organ Care System (OCS) Liver System, a portable organ perfusion and monitoring medical device.
Intended to preserve a donated liver in a near-physiologic, normothermic and functioning state, the OCS Liver System also optimizes liver function for eventual transplantation, according to a news release.
The FDA will meet at 9 a.m. ET today to review the PMA application. This story may be updated.